These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21493561)

  • 1. Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.
    Boswood A; Smith S; Patteson M
    Vet Rec; 2011 Feb; 168(8):222. PubMed ID: 21493561
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current use of pimobendan in canine patients with heart disease.
    Boswood A
    Vet Clin North Am Small Anim Pract; 2010 Jul; 40(4):571-80. PubMed ID: 20610012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
    Boswood A; McEwan JD; French A; Little C; Swift S; Smith S; Patteson M
    Vet Rec; 2003 Oct; 153(14):439-40. PubMed ID: 14582738
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ; Fine DM; Thombs LA; Gorelick JJ; Durham HE
    J Vet Intern Med; 2009; 23(6):1190-6. PubMed ID: 19780931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    Smith PJ; French AT; Van Israël N; Smith SG; Swift ST; Lee AJ; Corcoran BM; Dukes-McEwan J
    J Small Anim Pract; 2005 Mar; 46(3):121-30. PubMed ID: 15789807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease".
    Corcoran B; Culshaw G; Dukes-McEwan J; French A; Smith S; Swift S
    J Vet Intern Med; 2008; 22(2):243; author reply 245. PubMed ID: 18371020
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical trial results extend drug licence.
    Vet Rec; 2017 Nov; 181(18):466. PubMed ID: 29097560
    [No Abstract]   [Full Text] [Related]  

  • 11. A QUEST begins.
    Oyama MA
    J Vet Intern Med; 2008; 22(5):1076-8. PubMed ID: 18844829
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.
    Lombard CW; Jöns O; Bussadori CM
    J Am Anim Hosp Assoc; 2006; 42(4):249-61. PubMed ID: 16822763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
    Mizuno M; Yamano S; Chimura S; Hirakawa A; Takusagawa Y; Sawada T; Maetani S; Takahashi A; Mizuno T; Harada K; Shinoda A; Uchida S; Takeuchi J; Mizukoshi T; Endo M; Uechi M
    J Vet Med Sci; 2017 Jan; 79(1):29-34. PubMed ID: 27644192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded and randomized study".
    Le Bobinnec G
    J Vet Intern Med; 2008; 22(2):243-4; author reply 245-6. PubMed ID: 18371019
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N; Nolte I; Wall L; Sehn M; Raue J; Pilgram A; Rumstedt K; Bach JP
    BMC Vet Res; 2019 Jul; 15(1):237. PubMed ID: 31288807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimobendan and its use in treating canine congestive heart failure.
    Bowles D; Fry D
    Compend Contin Educ Vet; 2011 Nov; 33(11):E1. PubMed ID: 22101450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
    J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ; Block CL; Laughlin DS; Oyama MA
    J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimobendan in heart failure therapy--a silver bullet?
    Gordon SG; Miller MW; Saunders AB
    J Am Anim Hosp Assoc; 2006; 42(2):90-3. PubMed ID: 16527909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.